Arabic Arabic English English French French German German

Designing First-In-Human Trials for Small Molecules and Biologics

Martha Donoghue, MD, in the Office of Oncologic Diseases at CDER, discusses key design considerations for first-in-human trials of oncology drugs including, defining patient populations for eligibility, selection of the appropriate starting dose, dose escalation design, minimizing patient risk, dose optimization, and initial assessment of antitumor activity.
Learn more at:
FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.  
Upcoming Training –   
SBIA Listserv –
SBIA 2021 Playlist –
SBIA LinkedIn –  
SBIA Training Resources –  
Twitter –  
Email –  
Phone – (301) 796-6707 I (866) 405-5367

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Getting to First-in-Human for Small Molecules and Biologics

Next Post

Planning for Co-development of Companion Diagnostics

Related Posts